SCHEMBL5983014

SCHEMBL5983014

CC(C)NC(=O)CCCCCCn1c[c]nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
FAAH O00519 1/20 0.47
MAPK1 P28482 1/20 0.47
KDM4E B2RXH2 3/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HTT P42858 2/20 0.36
GAA P10253 1/20 0.36
BACE1 P56817 1/20 0.35
EPHX2 P34913 1/20 0.34
BRD4 O60885 2/20 0.34
TBXAS1 P24557 4/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
SMYD3 Q9H7B4 1/20 0.33
NLRP1 Q9C000 1/20 0.33
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5983183 1.00 MEN1 (0.47) MEN1KMT2AFAAHMAPK1KDM4E
SCHEMBL5982271 1.00 MEN1 (0.47) MEN1KMT2AFAAHMAPK1KDM4E
SCHEMBL5982169 0.99 MEN1 (0.45) MEN1KMT2AFAAHMAPK1KDM4E
SCHEMBL5982540 0.94 MEN1 (0.42) MEN1KMT2AFAAHMAPK1KDM4E
SCHEMBL5983694 0.88 KDM4E (0.39) MEN1KMT2AFAAHMAPK1KDM4E
SCHEMBL5982322 0.84 FAAH (0.39) FAAHTBXAS1LMNA
SCHEMBL5983580 0.84 FAAH (0.39) FAAHTBXAS1LMNA
SCHEMBL5983159 0.84 FAAH (0.39) FAAHTBXAS1LMNA
SCHEMBL6272232 0.82 FAAH (0.37) FAAHTBXAS1LMNA
SCHEMBL5982733 0.82 FAAH (0.47) FAAHKDM4EHPGDHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634888-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2006-03-15 EP disclosed
EP-1600451-A2 Synthesis of 2'-deoxy-l-nucleosides Pharmasset Limited (US) 2005-11-30 EP disclosed
EP-1600452-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2005-11-30 EP disclosed
US-20050090660-A1 2'-deoxy-L-nucleosides PHARMASSET, INC. 2005-04-28 US disclosed
US-5614519-A (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists KARL THOMAE GMBH (DE) 1997-03-25 US disclosed
US-5602127-A ADMINISTERING TO TREAT HYPERTENSION KARL THOMAE GMBH (DE) 1997-02-11 US disclosed
US-5594003-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-14 US disclosed
US-5591762-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-07 US disclosed
EP-0552765-B1 Benzimidazoles, pharmaceutical compositions containing them and process for their preparation THOMAE GMBH DR K (DE) 1996-08-14 EP disclosed
US-5459147-A Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma DR. KARL THOMAE GMBH (DE) 1995-10-17 US disclosed
EP-0556789-A2 Substituted biphenyl derivatives, therapeutic agents containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1993-08-25 EP disclosed
EP-0552765-A1 Benzimidazoles, pharmaceutical compositions containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1993-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090660-A1 2'-deoxy-L-nucleosides CCNH, ADAR, NSUN2 MEN1 3823/4885KMT2A 2174/4885FAAH 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.